Can a pill clear psoriasis on hands and feet?

NCT ID NCT07752108

Not yet recruiting Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Aug 07, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This trial tests whether an oral medication called zasocitinib (TAK-279) can reduce the redness, thickening, scaling, and painful cracks of palmoplantar psoriasis, a type of psoriasis that affects the palms and soles. Adults with moderate-to-severe non-pustular palmoplantar psoriasis will take the drug daily for up to a year or more, with regular clinic visits to monitor progress. The study aims to see if the treatment can make the skin clear or almost clear, and whether it improves the area affected by psoriasis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
zasocitinib (TAK-279), an oral tablet
What this could lead to
If successful, this could offer a new oral treatment option for people with hard-to-treat palmoplantar psoriasis, potentially improving quality of life by reducing pain, itching, and scaling on hands and feet.
What could go wrong
This is an early-phase study with a small number of participants, so results may not apply to everyone. The drug may not work as hoped or could cause side effects, and long-term benefits are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PALMOPLANTAR PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.